Vision Impairments



Peripheral Vision Training Study


Conditions:   Visual Impairment;   Cognitive Change
Intervention:   Other: computerized training
Sponsor:   University of Alabama at Birmingham
Recruiting - verified May 2017


MRI Screening for Auditory Pathway Malformations in Visually Impaired Children


Condition:   Visual Impairment
Intervention:  
Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild
Recruiting - verified September 2016


Perception of Objects and Natural Scenes in People With Vision Loss (ACTIVIS)


Condition:   Vision Loss
Intervention:   Other: vision tests
Sponsors:   Lille Catholic University;   University Hospital, Lille
Completed - verified August 2016


24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.


Condition:   Visual Impairment Due to Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: Aflibercept
Sponsor:   Novartis Pharmaceuticals
Withdrawn - verified April 2017


Evaluation of Tests Performance on a New Digital Orthoptic Platform


Conditions:   Binocular Vision Disorder;   Visual Impairment
Intervention:  
Sponsor:   University Hospital, Brest
Completed - verified April 2017


The Baltimore Reading and Eye Disease Study


Conditions:   Refractive Error;   Visual Impairment;   Convergence Insufficiency;   Reading Disabilities
Interventions:   Behavioral: Eyeglass wearing;   Behavioral: Orthoptic exercises;   Other: Specialist referral
Sponsor:   Johns Hopkins University
Active, not recruiting - verified March 2017


Modification in Cortical Activation in Pseudophakic Patients With Visual Difficulties After a Multifocal Implantation


Condition:   Vision Disorders
Intervention:   Other: fMRI
Sponsor:   University Hospital, Toulouse
Withdrawn - verified May 2016


Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema


Condition:   Visual Impairment Due to Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: Aflibercept
Sponsor:   Novartis Pharmaceuticals
Withdrawn - verified October 2016


A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese DME Patients


Conditions:   Diabetic Macular Edema;   Visual Impairment
Interventions:   Drug: ranibizumab;   Procedure: laser
Sponsor:   Novartis Pharmaceuticals
Completed - verified March 2017


Observation of Treatment Patterns With Lucentis in Approved Indications


Condition:   Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Intervention:  
Sponsor:   Novartis Pharmaceuticals
Completed - verified February 2017


A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.


Condition:   Choroidal Neovascularization Secondary to Pathologic Myopia
Intervention:   Drug: Ranibizumab
Sponsor:   Novartis Pharmaceuticals
Completed - verified May 2017


Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)


Condition:   Central Retinal Vein Occlusion
Interventions:   Other: Sham injection;   Drug: Ranibizumab 0.5 mg
Sponsor:   Novartis Pharmaceuticals
Completed - verified March 2017


Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD


Condition:   Visual Impairment Due to Neovascular AMD
Interventions:   Drug: Ranibizumab;   Drug: Aflibercept
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified November 2016


Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia


Condition:   Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Interventions:   Drug: Ranibizumab 0.5mg;   Drug: Rranibizumab 0.5 mg;   Drug: Verteporfin PDT
Sponsor:   Novartis Pharmaceuticals
Completed - verified May 2017


Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.


Condition:   Choroidal Neovascularization (CNV)
Interventions:   Drug: Ranibizumab;   Other: Sham control
Sponsor:   Novartis Pharmaceuticals
Completed - verified August 2016


Nitisinone for Type 1B Oculocutaneous Albinism


Conditions:   Albinism;   Vision Loss
Intervention:   Drug: Nitisinone (NTBC)
Sponsors:   National Eye Institute (NEI);   National Human Genome Research Institute (NHGRI)
Active, not recruiting - verified April 14, 2017


Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion


Condition:   Branch Retinal Vein Occlusion
Interventions:   Drug: Ranibizumab;   Procedure: Laser
Sponsor:   Novartis Pharmaceuticals
Completed - verified September 2016


Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion


Conditions:   Macular Edema;   Central Retinal Vein Occlusion
Intervention:   Drug: Ranibizumab 0.5 mg/0.05 ml
Sponsor:   Novartis Pharmaceuticals
Completed - verified September 2016


Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)


Conditions:   Visual Impairment;   Macular Edema;   Central Retinal Vein Occlusion
Interventions:   Drug: Ranibizumab;   Drug: Dexamethasone implant and sham injections
Sponsor:   Novartis Pharmaceuticals
Completed - verified September 2016


Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration


Condition:   Age Related Macular Degeneration
Interventions:   Device: Telescope prosthesis;   Device: WA-NG Telescope Prothesis
Sponsor:   VisionCare, Inc.
Withdrawn - verified October 2016


A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema


Conditions:   Visual Impairment;   Macular Edema
Intervention:   Drug: Ranibizumab
Sponsor:   Novartis Pharmaceuticals
Completed - verified February 2017


Low Vision Intervention Trial II (LOVIT II)


Condition:   Central Vision Loss From Macular Diseases
Interventions:   Other: Interdisciplinary Low Vision Service;   Other: Basic Low Vision Service
Sponsor:   VA Office of Research and Development
Completed - verified July 2016


Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema


Conditions:   Diabetic Macular Edema;   Visual Impairment
Interventions:   Drug: RFB002;   Procedure: Laser photocoagulation
Sponsor:   Novartis Pharmaceuticals
Completed - verified July 2014


Health Intervention for Adolescents With Intellectual Disability


Conditions:   Vision Impairment;   Hearing Impairment;   Obesity
Intervention:   Behavioral: Health Intervention Package
Sponsors:   The University of Queensland;   National Health and Medical Research Council, Australia
Completed - verified May 2015


Providing Access to the Visual Environment


Condition:   Vision Impairment
Intervention:  
Sponsors:   Vanderbilt University;   Tennessee Department of Education
Recruiting - verified October 2016

Refine Your Search Advanced Search